American Society of Hematology Annual Meeting

Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited

December 7th 2020, 2:00pm

Article

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020, 7:30pm

Article

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Interventions Improve Survival, Quality of Life for Patients Experiencing Financial Toxicity

December 6th 2020, 7:00pm

Article

Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.

How Higher Doses of Imetelstat May Benefit Patients with Relapsed/Refractory Myelofibrosis

December 6th 2020, 6:23pm

Video

In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

December 5th 2020, 9:33pm

Article

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020, 9:07pm

Article

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

December 5th 2020, 8:00pm

Article

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

MDM2 Inhibitor Shows Promise For Patients With AML

December 24th 2019, 12:00am

Video

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

Real-World Data Shows Promise for Patients on CAR-T Therapy

December 20th 2019, 12:00am

Video

Real-world data shows that CAR-T therapy can lower costs for patients with pre-existing comorbidities outside of the clinical setting.

Three-Drug Combination Improves Progression-Free Survival in Patients with Multiple Myeloma

December 11th 2019, 3:00am

Article

Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.